A population model for the leukopenic effect of etoposide*
Authors:
- Rüdiger E. PortRPRüdiger E. Port
- Mark J. RatainMRMark J. Ratain
- Lewis B. SheinerLSLewis B. Sheiner
- 1 March 1995
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 57 (3) , 325-334
Abstract
We present a new model-dependent approach to quantify hematologic toxicity in a patient population after anticancer therapy. The population model consists of three submodels that are simultaneously fit to the data: (1) a cubic spline function describing the average response of the population versus time ("structural model"), (2) a covariate model, which relates parameters of the structural model to measured demographic or therapeutic variables that are found to be of predictive value (in this study: white blood cell (WBC) count baseline, drug concentration, serum albumin, and serum bilirubin concentration), and (3) a variance model, which estimates the contribution to the response from random variability between patients and from variability within patients, both between courses and within courses, between days. To demonstrate the approach, previously reported data from 118 courses of etoposide therapy in 71 patients with cancer were used to model the decrease in WBC count after 3-day continuous infusions of drug. The estimated typical response profile is characterized by (1) a lag-time of 4 1/2 days before any WBC count decline is observed, (2) a duration of time below baseline of 22 days, and (3) half-maximal effect (i.e., decrease to 50% of baseline WBC count) after exposure to C50 = 3 mg/L etoposide (mean) over 3 days. Lower serum albumin concentrations, higher bilirubin concentrations, or both are associated with greater effects at a given etoposide exposure. Large variability in the estimated response was found between individuals and within individuals, between courses. The total variabilities (SD) in lag-time, duration of the decrease, and C50 were 1 day, 6 days, and 1.8 mg/L, respectively. The population model can also be used to predict the consequence of as-yet untested therapy and sampling strategies, as well as to relate acceptable risks of toxicity to target drug exposure.Keywords
This publication has 10 references indexed in Scilit:
- Building population pharmacokineticpharmacodynamic models. I. Models for covariate effectsJournal of Pharmacokinetics and Biopharmaceutics, 1992
- Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity.Journal of Clinical Oncology, 1991
- A three-step approach combining bayesian regression and NONMEM population analysis: Application to midazolamJournal of Pharmacokinetics and Biopharmaceutics, 1991
- Combining Physiologic Models and Symbolic Methods to Interpret Time-Varying Patient Data*Methods of Information in Medicine, 1991
- Changes in the clearance of total and unbound etoposide in patients with liver dysfunction.Journal of Clinical Oncology, 1990
- Pharmacodynamics in cancer therapy.Journal of Clinical Oncology, 1990
- Adaptive control of etoposide administration: Impact of interpatient pharmacodynamic variabilityClinical Pharmacology & Therapeutics, 1989
- Altered protein binding of etoposide in patients with cancerClinical Pharmacology & Therapeutics, 1989
- High-performance liquid chromatographic assay of mitomycin in biological fluidsJournal of Chromatography B: Biomedical Sciences and Applications, 1985
- Forecasting individual pharmacokineticsClinical Pharmacology & Therapeutics, 1979